Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.

Diabetes Obes Metab · 2026 · PMC12890774 · PMID 41504379

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a marginal trendno p-value reported

For SGLT‐2is in individuals with T2D, the RHRs for MACE, other cardiovascular endpoints, and kidney outcomes suggested comparable treatment benefits between sexes, with only a marginal trend towards greater benefit in men for cardiovascular death or HHF.

also in 626 other papers

a slight trendno p-value reported

Pooled RHRs showed no significant differences between sexes, aside from a slight trend suggesting greater benefit in women for cardiovascular death or HHF.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.